Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 659-669
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659
Table 2 Diagnostic performance of N-glycans, tumor markers in distinguishing patients with pancreatic ductal adenocarcinoma
Biomarker | AUC | Cut-off | Sensitivity | Specificity |
N-glycan | 0.86 | 0.28 | 84.90% | 73.00% |
CA19-9 | 0.75 | 37 | 55.91% | 95.49% |
CEA | 0.72 | 5.0 | 22.58% | 100.00% |
CA125 | 0.76 | 35 | 32.26% | 98.10% |
CA242 | 0.67 | 30 | 30.11% | 98.41% |
CA724 | 0.56 | 6.9 | 20.43% | 87.30% |
- Citation: Wen YR, Lin XW, Zhou YW, Xu L, Zhang JL, Chen CY, He J. N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer. World J Gastrointest Oncol 2024; 16(3): 659-669
- URL: https://www.wjgnet.com/1948-5204/full/v16/i3/659.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.659